Related Experiment Video
Updated: Mar 3, 2026
Simplified Intrafemoral Injections Using Live Mice Allow for Continuous Bone Marrow Analysis
Published on: November 10, 2023
[Treatment Selection of Elderly Acute Myeloid Leukemia Patients Guided by HCT-CI Score]
Wei Zhang1, Fang Fang1, Ying He1
1Department of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China.
Insights
The hematopoietic cell transplantation-comorbidity index (HCT-CI) score helps guide individualized treatment for elderly acute myeloid leukemia (AML) patients. Patients with lower HCT-CI scores benefit from chemotherapy, while higher scores indicate similar outcomes between chemotherapy and supportive care.
Area of Science:
- Hematology
- Oncology
- Geriatrics
Background:
- Elderly patients with acute myeloid leukemia (AML) present unique treatment challenges.
- Individualized treatment strategies are crucial for optimizing outcomes in this population.
- The hematopoietic cell transplantation-comorbidity index (HCT-CI) is a tool for assessing patient fitness.
Purpose of the Study:
- To evaluate the feasibility of using the HCT-CI score to guide individualized treatment strategies for elderly AML patients.
- To compare the efficacy and survival outcomes of different therapeutic regimens based on HCT-CI scores.
Main Methods:
- Retrospective analysis of clinical and biological data from 165 elderly AML patients (≥60 years).
- Patients were stratified by HCT-CI scores (0-1, 2-3, ≥4) and treatment groups (standard chemotherapy, low-dose chemotherapy, supportive therapy).
- Comparison of treatment efficacy, survival rates, and identification of prognostic risk factors using COX regression analysis.
Main Results:
- Patients with HCT-CI scores of 0-1 and 2-3 benefited significantly from chemotherapy compared to supportive care.
- No significant difference in survival rates was observed between chemotherapy and supportive therapy for patients with HCT-CI scores ≥4.
- Independent risk factors for poor prognosis included Eastern Cooperative Oncology Group Performance Status (ECOG-PS) ≥2, white blood cell (WBC) count ≥100×10^7/L, and HCT-CI score ≥4.
Conclusions:
- The HCT-CI score serves as a simple and feasible criterion for selecting individualized treatment strategies in elderly AML patients.
- HCT-CI stratification can help predict treatment response and guide therapeutic decisions, particularly distinguishing patients who benefit from chemotherapy.
Objective:
To explore the feasibility of guiding the individalized treatment strategy for elderly AML patients by using hematopoietic cell transplantation-comorbidity index(HCT-CI) score.
Methods:
The clinical and biological data of 165 elderly (260 years) AML patients in department of hematology of the first affiliated hospital of Wenzhou medical universtity from January 2000 to December 2014 were analyzed retrospectively. The AML patients were divided into 3 groups: score 0-1, 2-3 and ≥4 according to HCT-CI, then the patients in each group again were divided into standard chemotherapy group, low dose chemotherapy group and support therapy group accoriding to therapeutic regimens, and the efficacy of above mentioned 3 kinds of treatment and their effects on survival of ealderly AML patients were compared, the prognostic risk factors for patients were analyzed further.
Results:
A total of 165 patients (100%) were followed-up, and the mean follow-up time was 309 days, median survival time was 210 days. The survival analysis showed that the patients in HCT-CI score 0-1 group and 2-3 group banefited from chemotherapy, while the survival analysis of the HCT-CI score ≥4 group showed that there were no significant differance in survival rate between support therapy and chemotherapy groups. The complete remission rate and early mortality of patients received low dose or standard dose chemotherapy in HCT-CI score 0-1, 2-3 and ≥4 groups were not significantly different. Univariate analysis and multivariante analysis of COX ratio risk model showed that the EOCG-PS≥2, WBC≥100×107/L at initial diagnosis and HCT-CI score ≥4 were the independent risk factor affecting the prognosis of elderly AML patients. The median survival time of patients received chemotherapy and support therapy was 840 and 150 d(P<0.01) in HCT-CI score 0-1 group respectively, 210 and 60 days (P<0.01) in HCT-CI score 2-3 group respectively, 130 and 90 days (P>0.05) in HCT-CI score ≥4 group, respectively.
Conclusion:
The HCT-CI score can be used as simple and feasible evaluation criteria to judge the selection of individualized treatment strategy for elderly AML patients.
More Related Videos
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Related Concept Videos
01:22Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:21Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...